Euromonitor International
- Item successfully added to cart!
  
  Your cart is empty
  
  Check Out View Cart

Strategy Briefing

Analgesics Update Part 2: The Future of Pain Management

50 pages, Jun 2017

US$1,325

Add to cart Pay by invoice

New Report Guarantee

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!

About This Report

New Report Guarantee

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!

Part 2 of this global briefing series takes a deeper dive into the issues surrounding global analgesics sales, including how manufacturers are working around opioids, how a global patchwork of regulations affects sales in different regions, and how companies are positioning products around reformulation. This report concludes with a discussion of the future of pain management, and that while the market appears to be largely static and free from innovation, the reality is very much the opposite.

Files are delivered directly into your account within a few minutes of purchase.

Overview

Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Regulations differ widely across markets and have an important regional impact on analgesics sales

Countries across the world have widely varying regulatory structures when it comes to the active pharmaceutical ingredients (APIs) available to consumers, whether they be OTC, behind the counter, or only via a prescription (RX). When looking at sales of analgesics across markets, it is crucial then to take into account situations where an API might be available OTC in one market and RX in another, since its regulatory status will have a significant impact on its overall sales value.

The presence of opioid-derived analgesics drives regulatory changes and consumer concerns

Analgesics containing opioid APIs (such as codeine and dihydrocodeine) can take up important retail space in markets where they are available OTC, as opioids are extremely effective in managing pain and are often viewed as being more powerful than other systemic analgesics. Though opioid analgesics are leaving several markets due to safety concerns, they may be entering others as concerns about pain management in the developing world clashes with pharmacovigilance.

Opportunities for positioning occur across a number of metrics

Much of the innovation in analgesics is occurring along the lines of positioning, as companies seek to capture more of the consumer base by making existing products faster, longer lasting or smaller, to appeal to specific sectors of the consumer base, or by making existing products seem “new” through positioning them for more on-the-go consumers, athletes, or women, among other consumer groups.

Globally, the market for analgesics is much more dynamic than it appears to be

Over the review period of 2011-2016, the global analgesics market posted a CAGR of 2%, and will continue to post a CAGR of 2% through 2021. While it may appear that the market is relatively inelastic, the market is actually much more dynamic and driven by regulatory openings, the influence of opioids, and renewed positioning and reformulation, among other factors.

Want to find out more about this report?

Request more information

Introduction

Scope

Adult and paediatric systemic analgesics retail sales 2016

Key findings

Where Are We Now?

C hronic disease and elderly population driving analgesic sales

Innovation in analgesics is not easy…

…but the market is clamouring for it

And manufacturers are responding

Working Around Opioids

Analgesics sales by active ingredient are highly variable

Opioid-derivatives have largely exited the OTC market

Option 1: Reformulate them

Option 2: Refuse to use them

Option 3: Regulate them

Opioid-analgesics in Asia Pacific

Opioid-analgesics in Australasia

Opioid-analgesics in Eastern Europe

Opioid-analgesics in the Middle East and Africa

Opioid-analgesics in Latin America

Opioid-analgesics in North America

Opioid-analgesics in Western Europe

Regulations: A Global Patchwork

Country regulations reach beyond the RX/OTC classification

Analgesics freely available in some markets, restricted in others

Ingredient spotlight: OTC Triptans

Ingredient spotlight: Dipyrone

Ingredient spotlight: Ketoprofen

Opportunities in Reformulation

Making existing products “new” again

Make the pill easier to swallow

Make the punch stronger

Make the product work faster

Make it more absorbable

Make it time-relevant

Positioning: Dual action

Positioning: Physical location

Positioning: Sensorial effects

Positioning: Consumer demographic

Movement towards TENS

When is it enough?

The Future of Pain Management

Existing OTC analgesics are going to continue to do well

The “magic pill” is still a long way off

Consumers increasingly drawn to topicals

Will regulatory changes drive codeine drugs off the market?

Or will more codeine drugs enter the market?

Biggest potential area for growth remains RX-to-OTC switches

Final takeaway: Much more going on than meets the eye

Why buy this report?

Want to find out more about this report?

Request more information

Megatrends

Strategy Briefing

Analgesics Update Part 2: The Future of Pain Management

New Report Guarantee

About This Report

New Report Guarantee

Overview

Why buy this report?

Regulations differ widely across markets and have an important regional impact on analgesics sales

The presence of opioid-derived analgesics drives regulatory changes and consumer concerns

Opportunities for positioning occur across a number of metrics

Globally, the market for analgesics is much more dynamic than it appears to be

Want to find out more about this report?

Table of Contents

Introduction

Scope

Adult and paediatric systemic analgesics retail sales 2016

Key findings

Where Are We Now?

C hronic disease and elderly population driving analgesic sales

Innovation in analgesics is not easy…

…but the market is clamouring for it

And manufacturers are responding

Working Around Opioids

Analgesics sales by active ingredient are highly variable

Opioid-derivatives have largely exited the OTC market

Option 1: Reformulate them

Option 2: Refuse to use them

Option 3: Regulate them

Opioid-analgesics in Asia Pacific

Opioid-analgesics in Australasia

Opioid-analgesics in Eastern Europe

Opioid-analgesics in the Middle East and Africa

Opioid-analgesics in Latin America

Opioid-analgesics in North America

Opioid-analgesics in Western Europe

Regulations: A Global Patchwork

Country regulations reach beyond the RX/OTC classification

Analgesics freely available in some markets, restricted in others

Ingredient spotlight: OTC Triptans

Ingredient spotlight: Dipyrone

Ingredient spotlight: Ketoprofen

Opportunities in Reformulation

Making existing products “new” again

Make the pill easier to swallow

Make the punch stronger

Make the product work faster

Make it more absorbable

Make it time-relevant

Positioning: Dual action

Positioning: Physical location

Positioning: Sensorial effects

Positioning: Consumer demographic

Movement towards TENS

When is it enough?

The Future of Pain Management

Existing OTC analgesics are going to continue to do well

The “magic pill” is still a long way off

Consumers increasingly drawn to topicals

Will regulatory changes drive codeine drugs off the market?

Or will more codeine drugs enter the market?

Biggest potential area for growth remains RX-to-OTC switches

Final takeaway: Much more going on than meets the eye

Why buy this report?

Want to find out more about this report?

Recently Viewed

Complete Catalogue

Strategy Reports

Country Reports

Recently Viewed

Complete Catalogue

Strategy Reports

Country Reports